Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 EX-5.1
- 8.1 EX-8.1
- 8.2 EX-8.2
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 10.28 EX-10.28
- 10.31 EX-10.31
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.1 EX-99.1
- 99.3 EX-99.3
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- Download Excel data file
- View Excel data file
Associated filings
- 15 Jan 21 EFFECT Notice of effectiveness
- 14 Jan 21 424B3 Prospectus supplement
-
12 Jan 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 22 Dec 20 S-4 Registration of securities issued in business combination transactions
VIRX similar filings
Filing view
External links
Exhibit 99.4
January 12, 2021
Sunesis Pharmaceuticals, Inc.
395 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080
Consent to Reference in Registration Statement
Sunesis Pharmaceuticals, Inc. (the “Company”) has filed a Registration Statement on Form S-4, as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), as of the date hereof. In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the proxy statement/prospectus/information statement included in such registration statement as a future member of the board of directors of the Company.
Sincerely, |
/s/ Ivor Royston, M.D. |
Ivor Royston, M.D. |